XML 20 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net (loss) income $ (41,646) $ 50,264 $ 56,573
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 7,675 8,091 8,112
Net amortization of premiums on investment securities 1,899 3,466 4,970
Provision for credit losses 6,150 13,681 13,311
Share-based compensation 1,610 1,674 2,551
Provision for litigation settlement 23,022 0 0
Deferred income tax benefit (35,348) (1,348) (4,382)
Proceeds from sale of loans held for sale 34,491 19,316 31,556
Originations of loans held for sale (34,783) (19,570) (24,677)
Income on company owned life insurance (5,487) (12,106) (5,542)
Net gain on sale of loans held for sale (618) (566) (1,227)
Net loss on sale of investment securities 100,055 3,576 15
Net gain on sale of assets of subsidiary (13,658) 0 0
Net loss on other assets 44 6 16
Restructuring charges 35 114 1,619
Decrease (increase) in other assets 20,470 (56,076) (29,902)
Increase in other liabilities 13,216 372 80,580
Net cash provided by operating activities 77,127 10,894 133,573
Cash flows from investing activities:      
Purchases of available for sale securities (902,843) (51,472) (75,269)
Purchases of held to maturity securities (3,004) (3,145) (38,551)
Proceeds from principal payments, maturities and calls on available for sale securities 260,087 83,412 122,591
Proceeds from principal payments, maturities and calls on held to maturity securities 34,962 43,601 54,479
Proceeds from sales of securities available for sale 606,321 50,515 6,252
Net increase in loans (25,751) (420,234) (376,251)
Purchases of company owned life insurance, net of benefits received (30) (53,655) (35,564)
Proceeds from surrender of company owned life insurance 0 43,880 25,522
Proceeds from sale of assets of subsidiary 27,000 0 0
Purchases of premises and equipment (4,974) (2,992) (8,369)
Net cash used in investing activities (8,232) (310,090) (325,160)
Cash flows from financing activities:      
Net (decrease) increase in deposits (108,181) 283,488 102,334
Net (decrease) increase in short-term borrowings (86,000) (20,000) 175,000
Repurchase of preferred stock (7) 0 0
Proceeds from issuance of common stock 108,572 0 0
Issuance of long-term debt 0 50,000 0
Purchases of common stock for treasury (426) (571) (15,340)
Cash dividends paid to preferred shareholders (1,459) (1,459) (1,459)
Cash dividends paid to common shareholders (18,515) (18,286) (17,594)
Net cash (used in) provided by financing activities (106,016) 293,172 242,941
Net (decrease) increase in cash and cash equivalents (37,121) (6,024) 51,354
Cash and cash equivalents, beginning of period 124,442 130,466 79,112
Cash and cash equivalents, end of period $ 87,321 $ 124,442 $ 130,466